Details of the Drug

General Information of Drug (ID: DM6CWSO)

• Drug Name: Defibrotide
• Synonyms: Defitelio; Defibrotide (iv, veno-occlusive disease); Defibrotide (iv, veno-occlusive disease), Gentium

Indication

Disease Entry	ICD 11	Status	REF
Hepatic veno-occlusive disease	DB98.6	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[2]
Diabetic nephropathy	GB61.Z	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]

• Affected Organisms: Humans and other mammals
• ATC Code:
  B01AX01: Defibrotide
  B01AX: Other antithrombotic agents
  B01A: ANTITHROMBOTIC AGENTS
  B01: ANTITHROMBOTIC AGENTS
  B: BLOOD AND BLOOD FORMING ORGANS
• Cross-matching ID:
  PubChem CID: 135565962
  UNII: 568FY5I1YI
  DrugBank ID: DB04932
  TTD ID: D0FM2W
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208114
• [2] Defibrotide FDA Label
• [3] ClinicalTrials.gov (NCT00358501) Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04335201) Defibrotide in COVID-19 Pneumonia. U.S. National Institutes of Health.